Cargando…

Norcantharidin reverses cisplatin resistance and inhibits the epithelial mesenchymal transition of human non-small lung cancer cells by regulating the YAP pathway

Mostrar otras versiones (1)

Non-small cell lung cancer (NSCLC) accounts for >80% of all lung cancer cases, which are the leading cause of cancer-related mortality worldwide. The clinical efficacy of available therapies for NSCLC is often limited due to the development of resistance to anticancer drugs, particularly to cispl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jin, Dan, Wu, Yan, Shao, Cuijie, Gao, Yong, Wang, Deqiang, Guo, Jiwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6072289/ https://www.ncbi.nlm.nih.gov/pubmed/29901163 http://dx.doi.org/10.3892/or.2018.6486

Ejemplares similares

Norcantharidin reverses cisplatin resistance and inhibits the epithelial mesenchymal transition of human non-small lung cancer cells by regulating the YAP pathway
por: Jin, Dan, et al.
Publicado: (2021)

Norcantharidin Inhibits Renal Interstitial Fibrosis by Blocking the Tubular Epithelial-Mesenchymal Transition
por: Li, Ying, et al.
Publicado: (2013)

Correction: Norcantharidin Inhibits Renal Interstitial Fibrosis by Blocking the Tubular Epithelial-Mesenchymal Transition
por: Li, Ying, et al.
Publicado: (2013)

The antineoplastic drug metformin downregulates YAP by interfering with IRF-1 binding to the YAP promoter in NSCLC
por: Jin, Dan, et al.
Publicado: (2018)

Retraction notice to ‘The antineoplastic drug metformin downregulates YAP by interfering with IRF-1 binding to the YAP promoter in NSCLC’ [EBioMedicine 37 (2018) 188–204]
por: Jin, Dan, et al.
Publicado: (2021)

WWC3 inhibits epithelial–mesenchymal transition of lung cancer by activating Hippo-YAP signaling
por: Han, Qiang, et al.
Publicado: (2018)

Norcantharidin Suppresses Colon Cancer Cell Epithelial-Mesenchymal Transition by Inhibiting the αvβ6-ERK-Ets1 Signaling Pathway
por: Peng, Cheng, et al.
Publicado: (2016)

Adiponectin inhibits migration and invasion by reversing epithelial-mesenchymal transition in non-small cell lung carcinoma
por: Cui, Enhai, et al.
Publicado: (2018)

Silibinin inhibits the migration, invasion and epithelial-mesenchymal transition of prostate cancer by activating the autophagic degradation of YAP
por: Dan, Weichao, et al.
Publicado: (2022)

MiR-195 suppresses the metastasis and epithelial–mesenchymal transition of hepatocellular carcinoma by inhibiting YAP
por: Yu, Shuo, et al.
Publicado: (2017)

SMARCA4 Depletion Induces Cisplatin Resistance by Activating YAP1-Mediated Epithelial-to-Mesenchymal Transition in Triple-Negative Breast Cancer
por: Kim, Jihyun, et al.
Publicado: (2021)

Helicobacter pylori CagA promotes epithelial mesenchymal transition in gastric carcinogenesis via triggering oncogenic YAP pathway
por: Li, Nianshuang, et al.
Publicado: (2018)

OR02-4 YAP1 Overexpression Associates With Worse Prognosis In Patients With Adrenal Tumors And YAP1 Inhibition By Verteporfin Reduces Tumorigenicity And Reverses Epithelial-mesenchymal Transition In Adrenocortical Tumor Cells
por: Bellido More, Candy, et al.
Publicado: (2019)

Regorafenib inhibits epithelial-mesenchymal transition and suppresses cholangiocarcinoma metastasis via YAP1-AREG axis
por: Chang, Yu-Chan, et al.
Publicado: (2022)

Association of the Epithelial–Mesenchymal Transition (EMT) with Cisplatin Resistance
por: Ashrafizadeh, Milad, et al.
Publicado: (2020)

The Tumor Suppressor CYLD Inhibits Mammary Epithelial to Mesenchymal Transition by the Coordinated Inhibition of YAP/TAZ and TGFβ Signaling
por: Pseftogas, Athanasios, et al.
Publicado: (2020)

Expression of YAP in endometrial carcinoma tissues and its effect on epithelial to mesenchymal transition
por: Cheng, Yun, et al.
Publicado: (2020)

Correction: Helicobacter pylori CagA promotes epithelial mesenchymal transition in gastric carcinogenesis via triggering oncogenic YAP pathway
por: Li, Nianshuang, et al.
Publicado: (2023)

Notch3 inhibits epithelial–mesenchymal transition by activating Kibra-mediated Hippo/YAP signaling in breast cancer epithelial cells
por: Zhang, X, et al.
Publicado: (2016)

Resveratrol Inhibits Cisplatin-Induced Epithelial-to-Mesenchymal Transition in Ovarian Cancer Cell Lines
por: Baribeau, Sébastien, et al.
Publicado: (2014)

Autophagy inhibition impairs the epithelial-mesenchymal transition and enhances cisplatin sensitivity in nasopharyngeal carcinoma
por: Su, Zhongwu, et al.
Publicado: (2017)

Isoliquiritigenin Inhibits Ovarian Cancer Metastasis by Reversing Epithelial-to-Mesenchymal Transition
por: Chen, Chen, et al.
Publicado: (2019)

Inhibition or Reversal of the Epithelial-Mesenchymal Transition in Gastric Cancer: Pharmacological Approaches
por: Kozak, Joanna, et al.
Publicado: (2020)

DCBLD2 Mediates Epithelial-Mesenchymal Transition-Induced Metastasis by Cisplatin in Lung Adenocarcinoma
por: Chen, Xiaosu, et al.
Publicado: (2021)

Cisplatin sensitivity is enhanced in non-small cell lung cancer cells by regulating epithelial-mesenchymal transition through inhibition of eukaryotic translation initiation factor 5A2
por: Xu, Guodong, et al.
Publicado: (2014)

Krüppel-Like Factor 4 Enhances Sensitivity of Cisplatin to Lung Cancer Cells and Inhibits Regulating Epithelial-to-Mesenchymal Transition
por: Liu, Shenggang, et al.
Publicado: (2016)

Fluid shear stress activates YAP to promote epithelial–mesenchymal transition in hepatocellular carcinoma
por: Yu, Hongchi, et al.
Publicado: (2021)

Exploring YAP1-centered networks linking dysfunctional CFTR to epithelial–mesenchymal transition
por: Quaresma, Margarida C, et al.
Publicado: (2022)

Deubiquitinating enzyme USP10 promotes osteosarcoma metastasis and epithelial–mesenchymal transition by stabilizing YAP1
por: Deng, Jianyong, et al.
Publicado: (2023)

WTX inhibits gastric cancer migration through the reversal of epithelial-mesenchymal transition
por: Ye, Danli, et al.
Publicado: (2018)

Withaferin A inhibits Epithelial to Mesenchymal Transition in Non-Small Cell Lung Cancer Cells
por: Kyakulaga, Al Hassan, et al.
Publicado: (2018)

UBE2C Induces Cisplatin Resistance via ZEB1/2-Dependent Upregulation of ABCG2 and ERCC1 in NSCLC Cells
por: Wu, Yan, et al.
Publicado: (2019)

MiR-363 inhibits cisplatin chemoresistance of epithelial ovarian cancer by regulating snail-induced epithelial-mesenchymal transition
por: Cao, Lanqin, et al.
Publicado: (2018)

Corrigendum to “UBE2C Induces Cisplatin Resistance via ZEB1/2-Dependent Upregulation of ABCG2 and ERCC1 in NSCLC Cells”
por: Wu, Yan, et al.
Publicado: (2020)

Ginsenoside Rg3 inhibits epithelial-mesenchymal transition (EMT) and invasion of lung cancer by down-regulating FUT4
por: Tian, Lili, et al.
Publicado: (2015)

Glucose promotes epithelial‐mesenchymal transitions in bladder cancer by regulating the functions of YAP1 and TAZ
por: Li, Shi, et al.
Publicado: (2020)

Verteporfin suppresses the proliferation, epithelial-mesenchymal transition and stemness of head and neck squamous carcinoma cells via inhibiting YAP1
por: Liu, Kui, et al.
Publicado: (2019)

GABAB receptor inhibits tumor progression and epithelial-mesenchymal transition via the regulation of Hippo/YAP1 pathway in colorectal cancer
por: Wang, Huihui, et al.
Publicado: (2021)

Upregulation of CD109 Promotes the Epithelial-to-Mesenchymal Transition and Stemness Properties of Lung Adenocarcinomas via Activation of the Hippo-YAP Signaling
por: Lee, Kang-Yun, et al.
Publicado: (2020)

Doxycycline reverses epithelial-to-mesenchymal transition and suppresses the proliferation and metastasis of lung cancer cells
por: Qin, Yuan, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_eu30e7cjqjg0nugni73qnkravt